Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants
July 13, 2020 21:40 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten...
Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
July 13, 2020 16:01 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market...
Altimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVID™
July 13, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from the preclinical studies of its...
Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID™
July 09, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., July 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into a teaming agreement with...
Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
June 30, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., June 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in the Company’s Phase 1b...
Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19
June 29, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from the U.S. Army Medical...
Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B
June 22, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19
June 01, 2020 07:00 ET
|
Altimmune, Inc.
Clearance of IND application received from the U.S. FDAPlanned Phase 1/2 outpatient clinical trial will focus on patients with early SARS-CoV-2 infection Placebo-controlled trial expected to commence...
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
May 13, 2020 17:18 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020...
Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors
May 12, 2020 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., May 12, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky, M.D. to its Board of...